Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Gynecologic 2CNS 2Gastrointestinal 1

Conditions

Liver Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 780Fluorouracil 638Capecitabine 575Gemcitabine 478Leucovorin 459Bevacizumab 445Irinotecan 444Cisplatin 338Radiotherapy 283Cetuximab 252Paclitaxel 180S 1 (combination) 176pembrolizumab 173Docetaxel 156Drug Therapy 147Nivolumab 146sintilimab 143tislelizumab 131apatinib 131130-nm albumin-bound paclitaxel 128Folfox protocol 121durvalumab 119Albumin-Bound Paclitaxel 117camrelizumab 107lenvatinib 106Panitumumab 106regorafenib 102Surgical Procedures, Operative 102Sorafenib 99Radiation 88

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × carotuximab × Gastrointestinal × Clear all
NCT01375569 2017-07-28

TRC105 for Liver Cancer That Has Not Responded to Sorafenib

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 10 charts
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡